← Leaderboards
Roger J. Hajjar
Icahn School Of Medicine At Mount Sinai
$21,947,839
Attributed
$32,885,744
Total exposure
18
Grants
15
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.7M · FY2008–18$10M$7.5M$5M$2.5M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
Funding mix
By agency
NIH$32,885,744 · 18
By mechanism
R01$21,812,657 · 12
P50$6,376,440 · 1
T32$2,167,154 · 1
P20$1,670,675 · 1
R42$818,818 · 1
R13$40,000 · 2
Top collaborators
- Bruce D Gelb5 shared
- Fadi Gabriel Akar4 shared
- Deborah Davis Ascheim3 shared
- Robert A Levine3 shared
- Mark Mercola3 shared
- David Dale Thomas3 shared
- Kenneth Michael Fish2 shared
- Thomas Weber2 shared
Most similar at Icahn School Of Medicine At Mount Sinai
Same institution · by research overlap
- Chiara Giannarelli$8,992,836
- Jeffrey Avins Glassberg$10,238,775
- Rajesh Vedanthan$7,287,873
- David Sachs$1,333,545
- Vahram Haroutunian$39,970,462
Others in their field
Top investigators on “Heart Failure”
- Judith S Hochman · New York University School Of Medicine$120,321,606
- David T Mauger · Pennsylvania State Univ Hershey Med Ctr$51,947,333
- Lisa P Jacobson · Johns Hopkins University$45,397,923
- Walter N Kernan · Yale University$42,197,025
- Dalane W Kitzman · Wake Forest University$40,701,149
- David Couper · Univ Of North Carolina Chapel Hill$37,959,091
Research focus
Heart FailureHeartCardiacMolecularSerca2aGene TransferBaseCalciumSarcoplasmic ReticulumAnimal ModelProteinsGene TherapyCardiac MyocytesMediatingUnited StatesPumpCa(2+)-Transporting AtpaseCellsCongestive Heart FailureVectorPathway InteractionsPhospholambanDesignFamily Suidae
Grant awards (54)
Therapeutic Mechanisms of Cardiac Progenitors in Ischemic Cardiomyopathy$840,689
R01 · FY2018 · HL · contact PI
Treating Ventricle and Valve: New Synergies for Ischemic LV Remodeling with MR$691,269
R01 · FY2018 · HL
Role of miR25 in Heart Failure$634,729
R01 · FY2018 · HL · contact PI
Small Molecule Therapy for the Treatment of Heart Failure$268,206
R42 · FY2018 · HL · contact PI
Therapeutic Mechanisms of Cardiac Progenitors in Ischemic Cardiomyopathy$840,689
R01 · FY2017 · HL · contact PI
Anti-AAV Antibodies as an Obstacle to Cardiac AAV Gene Therapy$821,439
R01 · FY2017 · HL · contact PI
Calcium Pump Activators for Heart Failure Therapy$795,914
R01 · FY2017 · HL
Targeting Abnormal Calcium Cycling Using Novel Gene Therapy Vectors$733,804
R01 · FY2017 · HL · contact PI
Treating Ventricle and Valve: New Synergies for Ischemic LV Remodeling with MR$691,269
R01 · FY2017 · HL
Role of miR25 in Heart Failure$640,963
R01 · FY2017 · HL · contact PI
Small Molecule Therapy for the Treatment of Heart Failure$550,612
R42 · FY2017 · HL · contact PI
SUMO1 and SERCA2a Function$423,750
R01 · FY2017 · HL · contact PI
Training Program in Molecular and Cellular Cardiology$157,548
T32 · FY2017 · HL
Anti-AAV Antibodies as an Obstacle to Cardiac AAV Gene Therapy$834,439
R01 · FY2016 · HL · contact PI
Calcium Pump Activators for Heart Failure Therapy$795,914
R01 · FY2016 · HL
Treating Ventricle and Valve: New Synergies for Ischemic LV Remodeling with MR$744,495
R01 · FY2016 · HL
Targeting Abnormal Calcium Cycling Using Novel Gene Therapy Vectors$733,804
R01 · FY2016 · HL · contact PI
Role of miR25 in Heart Failure$622,016
R01 · FY2016 · HL · contact PI
Training Program in Molecular and Cellular Cardiology$553,293
T32 · FY2016 · HL
SUMO1 and SERCA2a Function$423,750
R01 · FY2016 · HL · contact PI
Calcium Pump Activators for Heart Failure Therapy$808,914
R01 · FY2015 · HL
Targeting Abnormal Calcium Cycling Using Novel Gene Therapy Vectors$722,797
R01 · FY2015 · HL · contact PI
Role of miR25 in Heart Failure$645,269
R01 · FY2015 · HL · contact PI
Training Program in Molecular and Cellular Cardiology$537,538
T32 · FY2015 · HL
SUMO1 and SERCA2a Function$417,393
R01 · FY2015 · HL · contact PI
TRIP: Targeted Gene Therapy for the Treatment of Heart Failure$2,082,299
P50 · FY2014 · HL · contact PI
Targeting Abnormal Calcium Cycling Using Novel Gene Therapy Vectors$733,804
R01 · FY2014 · HL · contact PI
Training Program in Molecular and Cellular Cardiology$506,732
T32 · FY2014 · HL
SUMO1 and SERCA2a Function$415,275
R01 · FY2014 · HL · contact PI
TRIP: Targeted Gene Therapy for the Treatment of Heart Failure$2,125,769
P50 · FY2013 · HL · contact PI
Training Program in Molecular and Cellular Cardiology$412,043
T32 · FY2013 · HL
SUMO1 and SERCA2a Function$403,410
R01 · FY2013 · HL · contact PI
Gene Therapy with Cardiotropic Vectors for the Treatment of Heart Failure$399,376
R01 · FY2013 · HL · contact PI
TRIP: Targeted Gene Therapy for the Treatment of Heart Failure$2,168,372
P50 · FY2012 · HL · contact PI
Gene Therapy with Cardiotropic Vectors for the Treatment of Heart Failure$419,513
R01 · FY2012 · HL · contact PI
C-TRIP: Targeted Gene Therapy for the Treatment of Heart Failure (P20)$847,500
P20 · FY2011 · HL · contact PI
Gene Therapy with Cardiotropic Vectors for the Treatment of Heart Failure$423,750
R01 · FY2011 · HL · contact PI
C-TRIP: Targeted Gene Therapy for the Treatment of Heart Failure (P20)$823,175
P20 · FY2010 · HL · contact PI
Regression of cardiac hypertrophy$537,956
R01 · FY2010 · HL · contact PI
Genetic Editing of Ca Cycling in Diabetic Cardiomyopathy$423,750
R01 · FY2010 · HL · contact PI
Gene Therapy with Cardiotropic Vectors for the Treatment of Heart Failure$420,275
R01 · FY2010 · HL · contact PI
PICOT and Cardiac Hypertrophy$411,461
R01 · FY2010 · HL · contact PI
Targeting Calcium Cycling in a Pre-Clinical Model of Cardiac Dysfunction$337,902
R01 · FY2010 · HL · contact PI
Regression of cardiac hypertrophy$521,276
R01 · FY2009 · HL · contact PI
Genetic Editing of Ca Cycling in Diabetic Cardiomyopathy$423,750
R01 · FY2009 · HL · contact PI
PICOT and Cardiac Hypertrophy$411,461
R01 · FY2009 · HL · contact PI
Targeting Calcium Cycling in a Pre-Clinical Model of Cardiac Dysfunction$337,902
R01 · FY2009 · HL · contact PI
PICOT and Cardiac Hypertrophy$155,377
R01 · FY2009 · HL · contact PI
The Aging Heart: A Roadmap to Cardiac Independence$20,000
R13 · FY2009 · AG · contact PI
Cardiovascular Cell and Gene Therapy Conference III$10,000
R13 · FY2009 · HL · contact PI
Genetic Editing of Ca Cycling in Diabetic Cardiomyopathy$423,750
R01 · FY2008 · HL · contact PI
PICOT and Cardiac Hypertrophy$411,461
R01 · FY2008 · HL · contact PI
Targeting Calcium Cycling in a Pre-Clinical Model of Cardiac Dysfunction$337,902
R01 · FY2008 · HL · contact PI
Cardiovascular Cell and Gene Therapy Conference III$10,000
R13 · FY2008 · HL · contact PI